These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37019377)

  • 1. Modeling the interaction between donor-derived regulatory T cells and effector T cells early after allogeneic hematopoietic stem cell transplantation.
    Nishiyama N; Ruoff P; Jimenez JC; Miwakeichi F; Nishiyama Y; Yata T
    Biosystems; 2023 May; 227-228():104889. PubMed ID: 37019377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
    Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
    PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
    Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
    Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation.
    Meguri Y; Asano T; Yoshioka T; Iwamoto M; Ikegawa S; Sugiura H; Kishi Y; Nakamura M; Sando Y; Kondo T; Sumii Y; Maeda Y; Matsuoka KI
    Front Immunol; 2022; 13():891925. PubMed ID: 35983059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.
    Moatti A; Debesset A; Pilon C; Beldi-Ferchiou A; Leclerc M; Redjoul R; Charlotte F; To NH; Bak A; Belkacemi Y; Salomon BL; Issa F; Michonneau D; Maury S; Cohen JL; Thiolat A
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
    Yao Y; Wang L; Zhou J; Zhang X
    J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota intervention by pre and probiotics can induce regulatory T cells and reduce the risk of severe acute GVHD following allogeneic hematopoietic stem cell transplantation.
    Yazdandoust E; Hajifathali A; Roshandel E; Zarif MN; Pourfathollah AA; Parkhideh S; Mehdizadeh M; Amini-Kafiabad S
    Transpl Immunol; 2023 Jun; 78():101836. PubMed ID: 37037266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treg-targeted IL-2/anti-IL-2 complex controls graft-
    Thiolat A; Pilon C; Caudana P; Moatti A; To NH; Sedlik C; Leclerc M; Maury S; Piaggio E; Cohen JL
    Haematologica; 2024 Jan; 109(1):129-142. PubMed ID: 37706355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
    Yang K; Fan ZP; Liu QF; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
    Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED
    Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
    Chang YJ; Huang XJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
    Bertaina A; Roncarolo MG
    Front Immunol; 2019; 10():1342. PubMed ID: 31354695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.
    Dertschnig S; Gergely P; Finke J; Schanz U; Holler E; Holtick U; Socié G; Medinger M; Passweg J; Teshima T; Stylianou C; Oehen S; Heim D; Bucher C
    Transplant Cell Ther; 2023 Jan; 29(1):41.e1-41.e9. PubMed ID: 36343893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease.
    Hippen KL; Hefazi M; Larson JH; Blazar BR
    Front Immunol; 2022; 13():926550. PubMed ID: 35967386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of regulatory T cells on the graft-versus-leukemia effect.
    Pacini CP; Soares MVD; Lacerda JF
    Front Immunol; 2024; 15():1339318. PubMed ID: 38711496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
    Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
    Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
    Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
    Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
    Kennedy-Nasser AA; Ku S; Castillo-Caro P; Hazrat Y; Wu MF; Liu H; Melenhorst J; Barrett AJ; Ito S; Foster A; Savoldo B; Yvon E; Carrum G; Ramos CA; Krance RA; Leung K; Heslop HE; Brenner MK; Bollard CM
    Clin Cancer Res; 2014 Apr; 20(8):2215-25. PubMed ID: 24573552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.